SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Preeya K. Gupta, MD, discusses a clinical trial comparing the TearCare system with Restasis for the treatment of dry eye disease and meibomian gland dysfunction.
According to Gupta, patients in the SAHARA trial who were treated with TearCare were dosed once at baseline and again at 5 months, while patients treated with Restasis (cyclosporine ophthalmic emulsion 0.05%, Allergan) received one drop twice a day throughout treatment.
“TearCare was found to be superior and offered a greater improvement across (Read more...)